ZolpidemPrincipal Investigator: John Whyte, MD, PhD Trial location: MossRehab This trial seeks to define more precisely the proportion of patients in the vegetative and minimally conscious states (VS/MCS) who have a clinically meaningful response to zolpidem with improvement in their level of consciousness. It will use cutting-edge research methods (functional neuroimaging, event related potentials, [...]
|
MossRehab will soon begin the exclusive U.S. clinical trial for a new assistive technology called the ReWalk. The ReWalk is a motorized exoskeleton suit that enables patients with lower limb disabilities, including complete paralysis, to independently engage in ambulatory activities, such as standing, walking and in some cases climbing stairs.The ReWalk consists of a lightweight [...]
|
by H. Barbeau, PhD, R. Elashoff, PhD, D. Deforge, MD, J. Ditunno, MD, M. Saulino, MD, B.H. Dobkin, MD McGill University/Institut de Readaptation de Montreal, Montreal, Quebec, Canada. BACKGROUND: Timed walking speed for 6 to 15 m and the distance walked in 2 to 12 minutes are frequently used outcome measures in rehabilitation trials, presumably [...]
|
by Alberto Esquenazi, MD, Nathaniel Mayer, MD, Roser Garreta, MD Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, Philadelphia, Pennsylvania, USA. OBJECTIVE: To assess whether walking velocity could be improved in patients with disorders related to upper-motor neuron syndrome (UMNS) by treating elbow flexor spasticity with botulinum toxin type A (BoNTA). DESIGN: This was a [...]
|
by Mary G. Klein, PhD, Leonard E. Braitman, PhD, Roberta Costello, MS, RN, Mary Ann Keenan, MD, Albert Esquenazi, MD Moss Rehabilitation Research Institute, Albert Einstein Healthcare Network, Philadelphia, PA; Thomas Jefferson University, Philadelphia PA. OBJECTIVE: To examine factors associated with daily step activity, perceived activity, maximum walking speed, and walking speed reserve over time [...]
|
by Kate Boyd, MPT; Robin Myers, PT, NCS; Maria Lucas, PT MossRehab Neurologic Physical Therapy Residency Program, Philadelphia, PA Click here to view this poster.
|
MossRehab’s recent acquisition of the Lokomat — a robotic training assistant consisting of an exoskeleton mounted above a treadmill — will greatly enhance the process of helping patients relearn how to walk. The Lokomat’s exoskeleton, pictured at right, wraps around a patient’s hips, knees, and lower back. Via a computer, it can be programmed to [...]
|
by Alberto Esquenazi, MD; Nathaniel Mayer, MD; Roser Garreta, MD Objective: To assess whether walking velocity could be improved in patients with disorders related to upper-motor neuron syndrome (UMNS) by treating elbow flexor spasticity with botulinum toxin type A (BoNTA). Design: This was a prospective, open-label, multicenter, interventional evaluation. The study group of 15 patients [...]
|
by Mausam Patel, Mukul Talaty, PhD, Sylvia Ounpuu. Center for Motion Analysis, Connecticut Children’s Medical Center, Hartford, CT, USA. Biomechanical model assumptions affect the interpretation of the role of the muscle or joint moments to the segmental power estimated by induced acceleration analysis (IAA). We evaluated the effect of modeling the pelvis and trunk segments [...]
|
Dr. Esquenazi is currently working to advance the use of technology to treat spastic equinovarus foot – a common condition caused by neurological difficulties that positions the foot toe-down and turned-in. “Some 20 leg muscle combinations – in the posterior or anterior compartments of the leg, or a combination of both – can produce this [...]
|
Dr. Esquenazi is equally committed to streamlining gait analysis technology for aligning prosthetics and orthotics. “The current state of the art in smaller clinics is a prosthetist or clinician watching the patient walk,” explains Dr. Esquenazi. “Results are subjective and inconsistent – clinician experience and patient subjectivity are just two of many variables.” In a [...]
|
by Matteo Cioni, MD, Alberto Esquenazi, MD, Barbara Hirai, BS.Department of Experimental and Clinical Pharmacology, Medical School, University of Catania, Catania, Italy. OBJECTIVE: The aim of this study was to identify if botulinum toxin type A is a drug able to modify walking velocity, step length, and width of the base of support of adult [...]
|
